Please login to the form below

Not currently logged in
Email:
Password:

CTI

This page shows the latest CTI news and features for those working in and with pharma, biotech and healthcare.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma

and aminopeptidase inhibitor tosedostat for leukaemia, which is partnered with CTI Biopharma.

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint. ... conditional, with CTI required to submit the results to the EMA by the end of this year in support of its

  • Baxalta and CTI complete filing for Jakafi rival in US Baxalta and CTI complete filing for Jakafi rival in US

    dose of Novartis/Incyte's drug, which according to CTI accounts for the bulk of patients taking Jakafi in the US. ... Baxalta's former parent company Baxter  licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.

  • Baxter and CTI's Jakafi rival clears phase III trial Baxter and CTI's Jakafi rival clears phase III trial

    Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... Assuming positive results in both PERSIST trials CTI has predicted it could be in a position to file for approval of pacritinib later this year or early in

  • CTI launches cancer drug Pixuvri in UK CTI launches cancer drug Pixuvri in UK

    Nevertheless, the recommendation was an important one for CTI and the UK lymphoma community, paving the way for yesterday's launch. ... it any, effective treatment options,' said CTI's president and CEO Dr James Bianco.

  • Baxter licenses cancer drug from CTI in $172m deal Baxter licenses cancer drug from CTI in $172m deal

    Pacritinib is being investigated to treat blood disorder myelofibrosis. Cell Therapeutics Inc (CTI) has met its objective of finding a commercial partner for cancer candidate pacritinib by the end of the ... CTI is on track to initiate a second phase III

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics